Arcturus Therapeutics (Nasdaq: $ARCT) Stock Hub 2026: The CSL Break-Up, The Cystic Fibrosis Phase 3 Decision And $191.5 Million In Cash

01 What Arcturus Is After The August 2026 Reset

Arcturus Therapeutics is a San Diego messenger RNA company that spent the last two years turning itself from a vaccine partner into a rare-disease developer, and completed the turn in August 2026. Founded in 2013 and listed on Nasdaq, it describes itself as focused on liver and respiratory rare disease therapeutics, built on three enabling technologies: LUNAR lipid-mediated delivery, STARR self-amplifying mRNA, and its own drug substance and drug product manufacturing expertise.

The company developed KOSTAIVE, the first self-amplifying mRNA COVID vaccine approved anywhere in the world. That product is the reason Arcturus has revenue at all, and the reason its income statement looks so different from one year to the next. It is also no longer the centre of the story.

Two clinical programmes now carry the equity thesis, and both are in Phase 2 with data or decisions due within months:

• ARCT-032, an inhaled mRNA therapy delivering CFTR messenger RNA to the airways of people with cystic fibrosis who carry Class I, or null, mutations. These are patients that CFTR modulator drugs cannot help, because a modulator needs a protein to modulate. The decision on whether to advance into Phase 3 is expected in the fourth quarter of 2026.
• ARCT-810, an mRNA therapy that instructs the liver to produce the ornithine transcarbamylase enzyme in patients with OTC deficiency, the most common urea cycle disorder. Enrolment and dosing in the Phase 2 study are complete, and the company said on August 6, 2026 that data and the regulatory plan would be communicated later in the third quarter. In March 2026 the FDA, at a Type C meeting, described a path toward a pivotal paediatric study that requires additional exploratory data to establish the optimal dose and therapeutic effect.

Three things happened between the start of July and the middle of August 2026, and together they redefine the company. On July 2, 2026 Arcturus announced a strategic collaboration with Thermo Fisher Scientific covering Phase 3 manufacturing and clinical research for the cystic fibrosis programme. On August 3, 2026 it signed a termination and settlement agreement with CSL Seqirus, ending the vaccine partnership and taking back global rights to KOSTAIVE and the entire infectious disease portfolio. On August 6, 2026 it reported a quarter in which total revenue had fallen 89.5 per cent year on year while the cash balance still covered operations into the end of 2028.

The three-line version

• What it is. A clinical-stage mRNA company with one approved product it does not fully control commercially, two Phase 2 rare-disease programmes, and no financial debt.
• What it has. $191.5 million of cash at June 30, 2026, a stated runway of more than two and a half years through the end of 2028, and a share count that has barely moved in 2026.
• What it needs. A cystic fibrosis dataset good enough to justify a Phase 3, an OTC regulatory path that survives contact with the FDA, and something to do with a vaccine portfolio it has just taken back.

02 LUNAR, STARR And The Manufacturing Leg

Arcturus talks about three technologies, and they answer three different questions.

LUNAR is the delivery system: lipid nanoparticles that carry RNA into a target cell. Delivery is the discipline’s real bottleneck. Getting RNA into the liver has been solved reasonably well by the whole field; getting it into the airway epithelium, where cystic fibrosis lives, and doing so repeatedly without toxicity, has not. In December 2025 Arcturus published preclinical work showing that LUNAR particles delivered human CFTR mRNA to airway epithelia, restoring chloride channel function and mucociliary clearance in primary human cystic fibrosis cells and in a ferret model of the disease.

STARR is self-amplifying mRNA. A conventional mRNA molecule is translated into protein until it degrades. A self-amplifying construct carries the machinery to copy its own message inside the cell, with the aim of producing more protein from a smaller dose. In vaccines that has been validated: KOSTAIVE exists. In repeat-dose therapeutics it is a harder proposition, because expression duration, tolerability and immunogenicity have to hold up dose after dose rather than once or twice.

Manufacturing is the third leg, and the one that decides whether the other two ever reach a patient at scale. Arcturus makes its own drug substance and drug product, holds a joint venture in Japan called ARCALIS with Axcelead, and has now signed Thermo Fisher for Phase 3 supply of ARCT-032. The company states a patent portfolio of more than 500 patents and applications across the United States, Europe, Japan, China and other countries, as of January 31, 2026.

What the platform has not yet produced is a therapeutic, as distinct from a vaccine, that works in patients. That is the gap ARCT-032 and ARCT-810 exist to close, and it is the same gap that has defeated several better-funded RNA companies. mRNA is a class of molecule, not a guarantee of a medicine: tissue, dose, formulation, target, frequency and therapeutic window decide each case separately.

03 ARCT-032 In Cystic Fibrosis: What The Data Actually Said

Cystic fibrosis is caused by mutations in the CFTR gene, which produces a chloride channel at the surface of epithelial cells. Modulator drugs, dominated commercially by Vertex Pharmaceuticals, work by correcting or potentiating a CFTR protein that the patient still makes. Patients with Class I, or null, mutations make no functional protein at all, so there is nothing to modulate. ARCT-032 attempts to supply the instructions instead: inhaled mRNA that tells airway cells to build a working CFTR channel.

What the October 2025 interim data actually said

On October 21, 2025 Arcturus released interim results from the second cohort of its Phase 2 multiple ascending dose study, NCT06747858. Six Class I adults inhaled 10 mg of ARCT-032 daily for 28 days. The company reported:

• Mucus burden. High-resolution CT scans, analysed with FDA 510(k)-cleared artificial intelligence software from Thirona, showed reductions in mucus burden in four of the six participants, with decreases in both mucus plug number and mucus volume. The company headlined this as “meaningful trends of clinical activity”.
• Lung function, and this is the part that gets quoted selectively. The release states plainly that the initial analysis, comparing FEV1 from Day 1 to Day 28, “did not demonstrate meaningful improvement”. The improvement that gets cited comes from a post hoc exploratory analysis that used a different baseline and a different endpoint date: the average of two pre-treatment measurements, at screening and Day 1, compared with the Day 42 value, on the assumption of extended activity of the CFTR protein produced during dosing. On that basis four of six participants showed an average absolute increase of 3.8 per cent and a relative increase of 5.1 per cent in percent predicted FEV1. Arcturus added that the magnitude falls within the range of natural variability of FEV1 measurement and that such analyses warrant cautionary interpretation while providing directional signal.
• Safety. Generally safe and well tolerated. Treatment-related adverse events seen in the single-dose Phase 1 study appeared again in some participants over the first few doses and then ceased with continued dosing. No bronchospasm was reported, with or without bronchodilator pre-treatment. One serious adverse event occurred well after the end of the dosing period; the Data Monitoring Committee found no convincing evidence it was related to ARCT-032 and approved the study to proceed.

The structure of that readout is what makes it hard to price. Imaging moved, the primary comparison of lung function did not, and a reworked exploratory comparison moved within the band of natural variability. All three statements come from the same press release, and a headline in either direction misses at least one of them.

What is running now

The third cohort tested 15 mg daily over 28 days. The fourth cohort, the one that matters, is testing 10 mg daily for 12 weeks in up to 20 Class I adults, with ppFEV1, lung clearance index, two validated quality-of-life instruments and HRCT imaging all measured. Twelve weeks is the first duration at which a functional signal could plausibly separate from measurement noise. Enrolment is running in the United States, Israel and Turkey, the latter two chosen because Class I and null mutations are more prevalent there.

Two dates should not be conflated. Arcturus expects the decision on advancing into Phase 3 in the fourth quarter of 2026. The registry record for NCT06747858 carries a primary completion date of June 2027 and a listed enrolment of 33. A company deciding on Phase 3 before the registered primary completion is normal in an open-label study read cohort by cohort, but the two dates are not the same thing and should not be quoted as if they were.

04 The Thermo Fisher Collaboration And The Phase 3 Decision

On July 2, 2026 Arcturus announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialisation of ARCT-032, using Thermo Fisher’s Accelerator Drug Development platform.

The terms, as disclosed:

• Thermo Fisher provides Phase 3 manufacturing, clinical research and related services.
• If Phase 2 yields positive results, Arcturus expects to run the Phase 3 programme through Thermo Fisher’s PPD clinical research business.
• Subject to regulatory approval of ARCT-032, Thermo Fisher receives exclusive commercial manufacturing rights under a separate commercial agreement.
• In the August 6 results release, Arcturus described the Phase 3 decision as “triggering significant resources and support from Thermo Fisher”.
• The 10-Q filed August 6, 2026 adds the figures the press release did not. Under a series of agreements entered into in June 2026, Thermo Fisher has agreed to provide qualifying clinical manufacturing services worth up to $40.0 million, and on a decision to advance ARCT-032 into Phase 3, Arcturus has agreed to engage Thermo Fisher’s affiliate PPD for clinical research services worth up to a further $40.0 million, covering the Phase 3 trial and a related open-label extension study. As of June 30, 2026 no commercial supply agreement had been executed and no amounts had been recognised in relation to the commercial manufacturing provisions.

For a company with a market capitalisation near $300 million, that structure solves a real problem and creates a smaller one. It solves capacity: inhaled mRNA at Phase 3 scale is not something a 28-million-share biotech builds by itself, and up to $80.0 million of committed manufacturing and clinical research services, across the two agreements, is a large number against a $19.7 million quarterly burn. It creates dependency: the manufacturing rights are exclusive on approval, which means the economics of a commercial ARCT-032 are shared from the start rather than negotiated later from a position of strength.

The July 2 announcement disclosed no financial terms; the $40.0 million commitment appears only in the quarterly report. The cost of goods on a commercial product and the split of commercial economics remain undisclosed, and neither can be assumed favourable from what is public.

05 ARCT-810 In OTC Deficiency: Dosing Done, Data Due

OTC deficiency is the most common of the urea cycle disorders. A defective ornithine transcarbamylase enzyme leaves the liver unable to convert ammonia into urea, and ammonia is toxic to the brain and liver. Arcturus states that more than 5,000 people in the United States have the condition, with worldwide prevalence between one in 14,000 and one in 77,000. ARCT-810 delivers OTC mRNA to hepatocytes so the liver makes the missing enzyme itself.

Conceptually this is the original promise of mRNA medicine: temporary instructions to make a therapeutic protein, without permanently editing the genome. The advantage is reversibility. The disadvantage is that the dose has to be repeated, potentially for life, which makes long-term tolerability the central question rather than a footnote.

Where the programme stands, from the company’s own disclosures:

• The Phase 2 study, NCT06488313, has completed enrolment, and all enrolled subjects have completed study drug dosing, as stated on August 6, 2026. The registry lists an estimated nine participants and a primary completion date of June 1, 2026, and its record still reads as recruiting.
• Arcturus expects to communicate data and the regulatory plan later in the third quarter of 2026, which ends September 30.
• An End-of-Phase 2 meeting with the FDA is planned for the second half of 2026, covering the path forward across adult and paediatric development.
• In the first quarter of 2026 the company held a Type C meeting with the FDA on paediatric development strategy and said afterwards that it had a clear path toward initiating a pivotal trial, to be aligned further at the End-of-Phase 2 meeting.
• An earlier Phase 2 study of ARCT-810, NCT05526066, which ran from October 2022 with eight participants, is listed on the registry as terminated after completion of the first cohort at 0.3 mg/kg, with slow enrolment given as the reason rather than safety or efficacy.

The paediatric direction is the strategically interesting part. Arcturus has said it is broadening development to address newborns and young children with the most severe forms of the disease, including those for whom liver transplantation is the current answer. A therapy that defers or replaces transplantation in infants is a different commercial proposition from one that supplements existing management in adults, and a different regulatory conversation as well.

06 KOSTAIVE, BARDA And The FDA Wall

KOSTAIVE is the world’s first approved self-amplifying mRNA vaccine. It is approved in Japan, in the European Union since February 2025, and in the United Kingdom since January 2026, as a COVID-19 vaccine. Sales began in Japan in October 2024. As validation of the STARR platform, that record is genuine and hard to argue with.

As a business, it has run into the American regulator. Arcturus disclosed in its 2025 annual report that on September 5, 2025, the week before its planned submission of a Biologics License Application for KOSTAIVE, the FDA requested that the company delay the submission. In October 2025 the FDA informed Arcturus that although it had previously agreed the proposed data package could support a single-dose indication, on further consideration it found that additional data from a clinical endpoint efficacy study would be needed, under a revised COVID-19 vaccine regulatory framework.

The practical consequence is that the United States market for KOSTAIVE now requires a new efficacy trial rather than a filing. For a company of this size, that is not a delay, it is a different project, and it explains a great deal about why the vaccine portfolio has stopped being the centre of the strategy.

The rest of the infectious disease work sits in the same category of real but not near-term. Under a cost reimbursement contract signed with BARDA in August 2022, worth up to $63.2 million, Arcturus is developing a pandemic influenza vaccine using STARR. Dosing of an sa-mRNA candidate against pandemic avian influenza began in December 2024, and results received in the second half of 2025 indicated a favourable tolerability and safety profile with a robust and durable humoral immune response in young and older adults. BARDA spending appears in the accounts as $0.6 million of research expense in the second quarter of 2026, against $2.5 million a year earlier.

07 The CSL Seqirus Break-Up And What Came Back

The most consequential thing Arcturus did in 2026 was end a partnership.

On August 3, 2026, three days before reporting results, the company signed a termination and settlement agreement with CSL Seqirus, part of CSL Limited, closing the sa-mRNA collaboration after a joint review. The terms as disclosed in the 10-Q and the results release:

• Arcturus regains global rights to KOSTAIVE and to the broader infectious disease vaccine portfolio, including seasonal influenza, pandemic influenza, RSV and Epstein-Barr virus programmes.
• CSL Seqirus makes a one-time cash payment of $12.0 million.
• Arcturus is released from a liability and from repayment of an R&D credit with an aggregate value of approximately $16.0 million.
• The parties agreed to dismiss the arbitration before the International Chamber of Commerce, in which Arcturus was seeking payment of a milestone under the collaboration triggered by the European Commission’s marketing authorisation for a presentation of KOSTAIVE, and exchanged mutual releases of claims.
• Existing arrangements with Meiji Seika Pharma for the Northern Hemisphere 2026-2027 season continue, expected to end on or around June 30, 2027. From the 2027-2028 season Arcturus expects to work directly with Meiji on KOSTAIVE in Japan.
• Arcturus owes CSL Seqirus single-digit royalties and revenue-sharing payments on future commercialisation of the vaccine products formerly licensed under the collaboration, where CSL intellectual property is incorporated.

Read as an accounting event, this is $28 million of value moving to Arcturus in a single agreement, roughly a tenth of its market capitalisation, plus roughly $5.2 million of deferred revenue from CSL Seqirus that the company expects to recognise in the third quarter of 2026, and the end of an arbitration it had itself brought. Read as a strategic event, it is more ambiguous. A partner with global vaccine infrastructure has handed back the asset, and the company that now owns it outright has 28 million shares outstanding, no commercial organisation of its own and an FDA that wants a new efficacy study before it will consider an American filing.

Arcturus states it intends to evaluate opportunities to maximise future value, including development, commercialisation and partnering. In practice the portfolio is now an option: it costs little to hold, it could be re-partnered, and it has one approved product with real sales in Japan behind it. What it is not, on current disclosure, is a source of revenue that funds the rare disease pipeline, and the collapse in collaboration revenue set out below is what that looks like in the accounts.

08 Second Quarter 2026 In Numbers

Arcturus reported the second quarter on August 6, 2026, filing a Form 10-Q and furnishing the results release as an exhibit to an 8-K the same day.

The loss more than doubled year on year in the quarter, and the reason is on the revenue line rather than the cost line. Total revenue fell from $28.3 million to $3.0 million, a decline of 89.5 per cent, as recognition under the CSL Seqirus agreement wound down ahead of the termination signed on August 3. The split matters: collaboration revenue, the CSL line, went from $24.5 million to $0.9 million, down 96 per cent, while grant revenue went from $3.8 million to $2.1 million. Across the half total revenue fell from $57.7 million to $5.0 million.

Spending went in the opposite direction. Research and development dropped from $29.6 million to $17.5 million in the quarter, a 41 per cent reduction, and from $64.5 million to $39.0 million across the half. The company attributes this to lower salaries, wages, benefits and facilities costs as it concentrated on its highest-priority programmes. General and administrative expense was essentially flat at $11.0 million, with a small increase from legal fees partly offset by lower personnel and facilities costs.

The segment note breaks research spending down by programme, and the numbers are smaller than the narrative around them: LUNAR-CF cost $2.6 million net in the quarter, LUNAR-OTC $1.9 million, BARDA $0.6 million and LUNAR-COVID $0.4 million, against $8.7 million of payroll and benefits and $1.9 million of facilities and equipment. Direct spending on the two lead clinical programmes was $4.5 million in three months.

One consequence changes how the next four quarters will read. With the CSL agreement terminated, the collaboration line that has been shrinking all year is close to gone, and what remains is grant revenue: Arcturus stated in its first-quarter release that its “current primary revenue stream relates to our grant agreement with BARDA”. Roughly $5.2 million of deferred CSL revenue is expected to be recognised in the third quarter of 2026, which will flatter that quarter and not repeat. From here the loss is largely a function of the cost base rather than of a revenue line that can surprise.

09 Cash, Burn And A Runway Through 2028

Cash and cash equivalents stood at $191.5 million at June 30, 2026, against $230.9 million at December 31, 2025, a decrease of $39.4 million over the half. The company attributes the decrease primarily to cash used in clinical development, including the continued advancement of ARCT-032 and ARCT-810.

Management’s stated position, from the second-quarter release: a “strong balance sheet and cash runway of over two and a half years through year end 2028”. The formulation has moved out, not stayed still: the first-quarter release of May 7, 2026 said the runway extended “beyond the second quarter of 2028”.

Two observations from the filings rather than from the framing.

The runway statement does not yet include the CSL settlement. The $12.0 million cash payment and roughly $16.0 million of released liabilities come from an agreement signed on August 3, 2026, which is after the balance sheet date of June 30. Neither appears in the $191.5 million figure. Arcturus itself frames the settlement as strengthening the financial position, which means the runway commentary is, if anything, conservative on this specific point.

There is no going concern language and no debt. Total liabilities were $52.5 million at June 30, 2026, down from $57.2 million at the end of 2025, and the balance sheet carries no financial borrowings. Cash of $191.5 million represents 85 per cent of the $224.3 million of total assets. Against a market capitalisation of roughly $299 million, cash alone accounts for about two thirds of the market value, and book value per share is $6.04 against a share price near $10.50.

At a half-year operating cash outflow of $39.4 million, the run rate is roughly $19.7 million a quarter. That is the number to watch when the third-quarter report lands: if the Phase 3 decision on ARCT-032 goes forward, the cost base steps up materially, and Thermo Fisher’s involvement changes who bears that cost without eliminating it.

10 The Share Count That Did Not Move

The share count is where Arcturus differs most sharply from most small-cap biotech, and it is the single most underappreciated line in the filings.

Nine thousand shares of movement across seven months, or 0.03 per cent. For comparison, the median clinical-stage biotech funds itself by issuing equity more or less continuously.

The capacity to dilute exists, is disclosed, and was used as recently as last year. Arcturus has a Controlled Equity Offering sales agreement dated December 23, 2022, amended on August 7, 2023, with Cantor Fitzgerald, Wells Fargo Securities and William Blair, allowing sales of up to $200 million of common stock. During the three months ended December 31, 2025 the company sold 1,179,201 shares under it at a weighted average price of $10.38, raising approximately $12.2 million gross and $11.7 million net after $0.5 million of offering costs. In December 2025 it filed, and had declared effective, a replacement shelf registration on Form S-3 which continues to support that agreement.

What the filings state plainly is that during the six months ended June 30, 2026 the company did not offer or sell any shares under the sales agreement. A company with $191.5 million in the bank, no debt, and a share price that has risen 71.5 per cent year to date is not obliged to sell equity, and has not.

That restraint is a choice rather than a constraint, and it can be reversed on any morning: the sale of 1.18 million shares in the fourth quarter of 2025 is the proof that the facility gets used when the board wants it used. The shelf is effective, and a Phase 3 decision in the fourth quarter of 2026 is exactly the kind of moment at which a board decides to pre-fund. The absence of dilution in the first half of 2026 is evidence of discipline so far, not a commitment about 2027.

11 The Competitive Field: Modulators, And The RNA Crowd

Arcturus competes on two fronts that have almost nothing to do with each other.

In cystic fibrosis, against a drug class rather than a company

The comparator is not another mRNA developer but the CFTR modulators, where Vertex Pharmaceuticals is dominant. In its second-quarter 2026 investor presentation, dated August 3, 2026, Vertex stated that recent label expansions mean approximately 95 per cent of people with cystic fibrosis are now eligible for treatment with its CFTR modulators.

That figure defines Arcturus’s addressable population from the other end. ARCT-032 is aimed at Class I and null mutation patients, the group modulators cannot help by construction, plus those who do not benefit from them. It is a small, severe and genuinely unserved population. The commercial size of that population, and the price a payer would accept for an inhaled therapy dosed indefinitely, are open questions that no public disclosure currently answers.

In RNA platforms, against a crowded and now-excited field

Merlintrader’s ranking of the platform companies that could deliver the next major biotech re-rating, Who Will Be the Next Moderna?, places $ARCT alongside $BEAM, $NTLA, $CRSP, $SLS, $SANA, $PRME and $BNTX, and reaches a conclusion consistent with the sections above: if “next Moderna” is read literally as successor to mRNA, Arcturus is one of the most relevant names on the list, and the transition from vaccines to repeatable somatic therapies is the part that has not been demonstrated.

The table below compares market characteristics only. It says nothing about the relative merits of the science, which do not fit in a table.

Prices and performance are Finviz Elite readings taken during the session of August 20, 2026 and move continuously.

12 Market Snapshot: A Small Float, Heavily Shorted

The market data below was read on August 20, 2026 during the trading session. The last completed close was $10.28 on August 19, 2026.

Three features of this table matter more than the rest.

The float is tiny and heavily shorted. With 26.05 million shares in the float and short interest at 27.67 per cent of it, roughly one share in four available to trade has been sold short, and the short ratio of 12.52 says it would take about twelve and a half average sessions to cover. In a stock that normally trades 575,000 shares a day, that combination makes price moves violent in both directions and largely mechanical.

August 19 was a mechanical day. The stock opened at $9.41 against a previous close of $8.21, traded as high as $11.10 and closed at $10.28, a gain of about 25 per cent on 5.63 million shares, roughly ten times the daily average. Arcturus issued no press release and made no SEC filing on or around that date; its last announcement was the second-quarter release of August 6. The wider mRNA complex moved on the same days, and the retail feed attributed the move to Moderna’s rally. What can be verified is only the absence of a company-specific disclosure.

Institutional ownership of 88.05 per cent against a $299 million market capitalisation means the register is concentrated in professional hands while the tradeable float is small. That is a structure in which a single institutional decision moves the price more than any retail flow.

13 Retail Sentiment On Stocktwits

The readings below describe an audience, not a company. They are self-reported tags from non-professional traders on a public message board, and they carry no predictive claim.

Three themes ran through the stream in the days around August 19 and 20, and each is a belief rather than a fact. The first is the short squeeze, which follows arithmetically from 27.67 per cent of a 26-million-share float being sold short. The second is speculation that a larger mRNA company might acquire Arcturus for its pipeline and licences; no party has announced anything of the kind and no filing supports it. The third is momentum-scanner traffic, which describes options volume and alert triggers rather than the business.

The watcher count of 5,484 against a message volume reading at the top of its own range is the signature of a stock that has just moved. It says the crowd arrived; it does not say what the crowd knows.

14 The Catalyst Map To Mid-2027

Arcturus has an unusually dense calendar for a company this size, and unusually little of it is pinned to a specific day.

The structural point about this calendar is that the two events capable of re-rating the company, the OTC data and the cystic fibrosis Phase 3 decision, fall within roughly five months of each other and both sit inside the stated cash runway. That is a materially different position from a company that has to finance before it can find out.

15 Risks And Red Flags

The risks below come from the company’s own filings and from the structure of the balance sheet and the share register. They are descriptions, not forecasts.

• The collaboration revenue line has effectively gone. It fell 96 per cent year on year in the quarter, from $24.5 million to $0.9 million, and the agreement that produced it was terminated on August 3, 2026. What remains is grant revenue, which the company itself described in May as its current primary revenue stream, plus roughly $5.2 million of deferred CSL revenue expected in the third quarter that will not repeat.
• The lung function signal is not yet a result. The straightforward comparison, Day 1 against Day 28, did not demonstrate meaningful improvement. The 3.8 per cent figure comes from a post hoc analysis using a two-measurement baseline and a Day 42 endpoint, in four of six patients, and Arcturus itself placed the magnitude within the range of natural variability of FEV1 measurement. What moved on the primary imaging read-out was mucus, not function.
• A single Phase 3 decision carries most of the equity story. If the fourth-quarter 2026 decision on ARCT-032 is negative or deferred, the company is left with an OTC programme in a small population and a vaccine portfolio the FDA has asked for more data on.
• KOSTAIVE has no American path without a new efficacy study. The FDA asked Arcturus to delay its BLA on September 5, 2025 and in October 2025 said additional clinical endpoint efficacy data would be needed under a revised COVID-19 vaccine framework.
• Taking the vaccine portfolio back is not the same as monetising it. Arcturus now owns global rights it has no commercial organisation to exploit, owes CSL single-digit royalties and revenue sharing on future commercialisation of those products, and depends on Meiji in Japan through around June 30, 2027.
• Thermo Fisher holds exclusive commercial manufacturing rights on approval. The collaboration solves Phase 3 capacity and shares the economics of any commercial product from the outset. No financial terms were disclosed.
• The float is small and a quarter of it is short. Short interest at 27.67 per cent of a 26.05 million share float, with a short ratio of 12.52 and average volume of 575,000 shares, produces price behaviour that is driven by positioning as much as by news.
• Dilution capacity is live even though it has not been used. The sales agreement with Cantor Fitzgerald, Wells Fargo and William Blair remains in place and a replacement S-3 shelf was declared effective in December 2025. Nothing was sold in the first half of 2026; nothing prevents sales in the second.
• The registry and the guidance do not line up. NCT06747858 carries a primary completion date of June 2027 while the company guides a Phase 3 decision in the fourth quarter of 2026. The gap is explicable in an open-label cohort study, but it means the “decision” and the “completed trial” are separate events.
• The equity-method investment in ARCALIS is carried at zero. The Japanese manufacturing joint venture with Axcelead had a carrying value of nil at June 30, 2026.
• Arcturus is in litigation it started, and is now also a defendant in it. On September 23, 2025 the company sued AbbVie Inc., Capstan Therapeutics and other defendants in the Southern District of California for trade secret misappropriation and breach of contract. On March 30, 2026 the court granted the motion to dismiss in part and denied it in part, with leave to amend; an amended complaint followed on April 13, 2026. On May 11, 2026 the defendants answered and Capstan asserted counterclaims for trade secret misappropriation against Arcturus and two of its employees, and for breach of contract against the two employees. Arcturus and the employees answered on June 12, 2026, and no trial date has been set. Litigation consumes cash and management attention whichever way it resolves.
• An earlier Phase 2 in OTC deficiency was terminated. NCT05526066, which began in October 2022 with eight participants, is listed on the registry as terminated after the first cohort, with slow enrolment given as the reason rather than safety or efficacy. In a disease of this prevalence, recruitment is itself a programme risk.

16 Merlintrader Health Score

The Merlintrader Health Score is a 1 to 5 reading of how robust or fragile a biotech looks over the next twelve to eighteen months, built on five weighted pillars. It describes balance-sheet and execution resilience. It is not a rating, a target, or an indication to buy or sell anything.

The score would move up on a positive OTC dataset with a clear regulatory path, or a Phase 3 decision accompanied by twelve-week functional data. It would move down on a deferral of the Phase 3 decision, an equity raise at a discount, or any signal that the returned vaccine portfolio has become a cost rather than an option.

17 Scenarios

The paths below are descriptions of how the situation could develop, based on what is already on the record. They contain no probabilities, no price levels and no recommendation.

18 Bottom Line

Arcturus is the rare small-cap biotech whose balance sheet is not the problem.

It holds $191.5 million in cash with no financial debt, spends roughly $19.7 million a quarter, has told the market its runway reaches the end of 2028, and has issued nine thousand new shares in seven months. On top of that it has just collected $12 million in cash and shed about $16 million of liabilities by ending a partnership, and it has signed the manufacturing arm of Thermo Fisher to carry a Phase 3 it has not yet decided to run.

What it has not got is proof that its platform makes medicines rather than vaccines. KOSTAIVE demonstrates that self-amplifying mRNA can be approved; it does not demonstrate that inhaled mRNA restores lung function in cystic fibrosis, or that repeated liver dosing normalises ammonia in OTC deficiency. The October 2025 cystic fibrosis interim moved a pre-specified imaging endpoint and produced a lung function signal that the company itself placed inside the range of natural variability. That is an honest disclosure and an unresolved question at the same time.

The next five months answer more of it than the last five years did. The OTC data and regulatory plan are due before the end of September 2026, from a study where dosing is already complete. The cystic fibrosis Phase 3 decision is guided for the fourth quarter, informed by twelve-week dosing rather than twenty-eight days. Both fall inside the funded period, which is why the market’s attention has arrived before the data have.

For anyone tracking this name, the checkpoints are concrete: whether the OTC readout appears by September 30 and what it says about ammonia and tolerability, whether the Phase 3 decision is taken in the fourth quarter or deferred, whether the sales agreement stays untouched in the second half, and what Arcturus decides to do with a vaccine portfolio it now owns outright and cannot commercialise alone.

Related Research On Merlintrader

• Who Will Be the Next Moderna? SLS, BEAM, NTLA and the Biotech Stocks That Could See the Next Major Re-Rating — where $ARCT sits against seven other platform companies, with the same balance sheet and catalyst framework applied to each.
• Sana Biotechnology ($SANA) Stock Hub — the opposite balance sheet: a going concern statement, continuous dilution, and two programmes not yet in a registered trial.
• Biotech Stock Hubs & Catalyst Index 2026 — every biotech company hub on Merlintrader, each with its own update date.
• Top Ten Biotech Stocks Right Now — the names we are following most closely.
• Free Biotech Catalyst Calendar — PDUFA dates, advisory committees and clinical readouts in one filterable calendar.